Medulloblastoma (MB) is currently divided into at least five molecular subgroups that exhibit different genomic aberrations, gene expression profiles, and clinical outcomes as well as extensive intertumoral heterogeneity: WNT, Sonic Hedgehog (SHH)/TP53‐wild‐type, SHH/TP53 mutant, Group 3, and Group 4 (Cavalli et al., 2017; Louis et al., 2016; Northcott et al., 2011). The gene discussed is TP53; the disease is medulloblastoma.